Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $41.00 Average Target Price from Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have earned an average rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $41.00.

A number of research firms have weighed in on ASMB. Zacks Research raised shares of Assembly Biosciences to a “hold” rating in a research report on Tuesday, August 19th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research note on Tuesday, October 14th. Citizens Jmp initiated coverage on Assembly Biosciences in a research note on Wednesday, September 24th. They issued an “outperform” rating and a $38.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, October 8th. Finally, Mizuho set a $40.00 price objective on shares of Assembly Biosciences and gave the stock an “outperform” rating in a report on Thursday, November 20th.

Assembly Biosciences Price Performance

NASDAQ:ASMB opened at $35.87 on Monday. Assembly Biosciences has a one year low of $7.75 and a one year high of $39.71. The firm’s 50 day simple moving average is $31.95 and its 200 day simple moving average is $24.42. The company has a market cap of $567.46 million, a PE ratio of -7.49 and a beta of 1.14.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.22). Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%. The business had revenue of $10.79 million for the quarter, compared to the consensus estimate of $7.46 million. Equities research analysts expect that Assembly Biosciences will post -6.87 EPS for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Hedge funds have recently bought and sold shares of the company. Farallon Capital Management LLC bought a new position in shares of Assembly Biosciences during the third quarter valued at about $31,426,000. RA Capital Management L.P. purchased a new position in Assembly Biosciences in the third quarter worth $26,122,000. Commodore Capital LP bought a new position in Assembly Biosciences in the 3rd quarter valued at $25,600,000. Vanguard Group Inc. increased its position in shares of Assembly Biosciences by 97.8% during the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after purchasing an additional 248,287 shares during the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in shares of Assembly Biosciences during the 3rd quarter worth $6,425,000. 19.92% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.